Published in Methods Mol Biol on January 01, 2012
Cellular heterogeneity profiling by hyaluronan probes reveals an invasive but slow-growing breast tumor subset. Proc Natl Acad Sci U S A (2014) 0.95
3D printing of biomimetic microstructures for cancer cell migration. Biomed Microdevices (2014) 0.87
Molecular targeted viral nanoparticles as tools for imaging cancer. Methods Mol Biol (2014) 0.84
Stage of breast cancer progression influences cellular response to activation of the WNT/planar cell polarity pathway. Sci Rep (2014) 0.83
Improved method for ex ovo-cultivation of developing chicken embryos for human stem cell xenografts. Stem Cells Int (2013) 0.80
SNX9 promotes metastasis by enhancing cancer cell invasion via differential regulation of RhoGTPases. Mol Biol Cell (2016) 0.79
Multiphoton imaging reveals that nanosecond pulsed electric fields collapse tumor and normal vascular perfusion in human glioblastoma xenografts. Sci Rep (2016) 0.78
Emblica officinalis extract downregulates pro-angiogenic molecules via upregulation of cellular and exosomal miR-375 in human ovarian cancer cells. Oncotarget (2016) 0.78
Fibroblast Growth Factor Receptor-Dependent and -Independent Paracrine Signaling by Sunitinib-Resistant Renal Cell Carcinoma. Mol Cell Biol (2016) 0.76
Evaluating the effectiveness of cancer drug sensitization in vitro and in vivo. J Vis Exp (2015) 0.75
Metastasis as a therapeutic target in prostate cancer: a conceptual framework. Am J Clin Exp Urol (2014) 0.75
Targeting of CCBE1 by miR-330-3p in human breast cancer promotes metastasis. Br J Cancer (2017) 0.75
Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst (2002) 2.77
Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Res (2008) 2.63
Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. Cancer Res (2002) 2.36
Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res (2004) 2.33
In vivo magnetic resonance imaging of single cells in mouse brain with optical validation. Magn Reson Med (2006) 2.32
Does tumour dormancy offer a therapeutic target? Nat Rev Cancer (2010) 2.19
Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res Treat (2003) 2.14
Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth. Eur J Cancer (2010) 2.13
In vivo MRI of cancer cell fate at the single-cell level in a mouse model of breast cancer metastasis to the brain. Magn Reson Med (2006) 1.88
Cancer spread and micrometastasis development: quantitative approaches for in vivo models. Bioessays (2002) 1.76
The biology of metastasis to a sanctuary site. Clin Cancer Res (2007) 1.72
Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer. Breast Cancer Res Treat (2008) 1.59
New dual monoclonal ELISA for measuring plasma osteopontin as a biomarker associated with survival in prostate cancer: clinical validation and comparison of multiple ELISAs. Clin Chem (2009) 1.59
Histone ubiquitination: a tagging tail unfolds? Bioessays (2002) 1.56
KISS1R induces invasiveness of estrogen receptor-negative human mammary epithelial and breast cancer cells. Endocrinology (2013) 1.55
Dormancy of solitary metastatic cells. Cell Cycle (2006) 1.53
Role of the metastasis-promoting protein osteopontin in the tumour microenvironment. J Cell Mol Med (2010) 1.53
Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res (2006) 1.49
Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer (2002) 1.49
Cowpea mosaic virus nanoparticles target surface vimentin on cancer cells. Nanomedicine (Lond) (2011) 1.49
Osteopontin overexpression in breast cancer: knowledge gained and possible implications for clinical management. J Cell Biochem (2007) 1.48
Hydrazone ligation strategy to assemble multifunctional viral nanoparticles for cell imaging and tumor targeting. Nano Lett (2010) 1.42
Ghrelin receptor as a novel imaging target for prostatic neoplasms. Prostate (2011) 1.40
Breast cancer metastasis suppressor 1 (BRMS1) inhibits osteopontin transcription by abrogating NF-kappaB activation. Mol Cancer (2007) 1.40
Intravital imaging of embryonic and tumor neovasculature using viral nanoparticles. Nat Protoc (2010) 1.34
A flavonoid fraction from cranberry extract inhibits proliferation of human tumor cell lines. J Nutr (2004) 1.32
Targeting tumor cell motility to prevent metastasis. Adv Drug Deliv Rev (2011) 1.32
Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer. Am J Pathol (2006) 1.30
Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma, MDA-MB-435. Clin Exp Metastasis (2006) 1.30
Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways. Oncogene (2003) 1.29
Tumor dormancy and cancer stem cells: implications for the biology and treatment of breast cancer metastasis. Breast Dis (2007) 1.28
Osteopontin induces multiple changes in gene expression that reflect the six "hallmarks of cancer" in a model of breast cancer progression. Mol Carcinog (2005) 1.28
Epigenetic mapping and functional analysis in a breast cancer metastasis model using whole-genome promoter tiling microarrays. Breast Cancer Res (2008) 1.27
Enhanced cell surface CD44 variant (v6, v9) expression by osteopontin in breast cancer epithelial cells facilitates tumor cell migration: novel post-transcriptional, post-translational regulation. Clin Exp Metastasis (2006) 1.26
Beta(3) integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin. Mol Cancer Res (2003) 1.24
Tumour dormancy in breast cancer: an update. Breast Cancer Res (2007) 1.23
β1-integrin: a potential therapeutic target in the battle against cancer recurrence. Clin Cancer Res (2011) 1.23
Intravital imaging of human prostate cancer using viral nanoparticles targeted to gastrin-releasing Peptide receptors. Small (2011) 1.22
A new model for lymphatic metastasis: development of a variant of the MDA-MB-468 human breast cancer cell line that aggressively metastasizes to lymph nodes. Clin Exp Metastasis (2005) 1.20
The role of apoptosis in tumor progression and metastasis. Curr Mol Med (2003) 1.20
Brain metastases of breast cancer. Breast Dis (2007) 1.20
Transcriptional regulation of osteopontin and the metastatic phenotype: evidence for a Ras-activated enhancer in the human OPN promoter. Clin Exp Metastasis (2003) 1.18
Dietary genistein reduces metastasis in a postsurgical orthotopic breast cancer model. Cancer Res (2005) 1.18
Notch1 inhibition alters the CD44hi/CD24lo population and reduces the formation of brain metastases from breast cancer. Mol Cancer Res (2011) 1.18
Pre- and post-translational regulation of osteopontin in cancer. J Cell Commun Signal (2011) 1.17
Detection and quantification of circulating tumor cells in mouse models of human breast cancer using immunomagnetic enrichment and multiparameter flow cytometry. Cytometry A (2005) 1.16
Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo. Mol Ther (2007) 1.16
In vivo characterization of changing blood-tumor barrier permeability in a mouse model of breast cancer metastasis: a complementary magnetic resonance imaging approach. Invest Radiol (2011) 1.14
Three-dimensional high-frequency ultrasound imaging for longitudinal evaluation of liver metastases in preclinical models. Cancer Res (2005) 1.13
Increased tumor homing and tissue penetration of the filamentous plant viral nanoparticle Potato virus X. Mol Pharm (2012) 1.13
Time-course characterization of the computed tomography contrast enhancement of an iodinated blood-pool contrast agent in mice using a volumetric flat-panel equipped computed tomography scanner. Invest Radiol (2006) 1.12
Structural characterization of macroH2A containing chromatin. Biochemistry (2004) 1.11
Multi-platform whole-genome microarray analyses refine the epigenetic signature of breast cancer metastasis with gene expression and copy number. PLoS One (2010) 1.09
Nuclear localization of maspin is essential for its inhibition of tumor growth and metastasis. Lab Invest (2011) 1.07
Downregulation of osteopontin contributes to metastasis suppression by breast cancer metastasis suppressor 1. Int J Cancer (2008) 1.04
Tumor dormancy and metastasis. Adv Cancer Res (2009) 1.04
Osteopontin and colon cancer progression. Clin Exp Metastasis (2003) 1.04
Estrous cycle influences organ-specific metastasis of B16F10 melanoma cells. Cancer Res (2003) 1.03
Micrometastatic disease and metastatic outgrowth: clinical issues and experimental approaches. Future Oncol (2009) 1.02
Negative associations between corpus callosum midsagittal area and IQ in a representative sample of healthy children and adolescents. PLoS One (2011) 1.02
Osteopontin (Eta-1) and fibroblast growth factor-2 cross-talk in angiogenesis. J Immunol (2003) 1.00
Molecular mechanisms of metastasis. Cancer Metastasis Rev (2006) 1.00
Gene signatures of breast cancer progression and metastasis. Breast Cancer Res (2011) 0.99
Surface-enhanced laser desorption/ionization-time of flight-mass spectrometry (SELDI-TOF-MS): a new proteomic urinary test for patients with urolithiasis. J Clin Lab Anal (2004) 0.97
Osteopontin identified as colon cancer tumor progression marker. C R Biol (2004) 0.96
Embryonic protein nodal promotes breast cancer vascularization. Cancer Res (2012) 0.96
Cellular heterogeneity profiling by hyaluronan probes reveals an invasive but slow-growing breast tumor subset. Proc Natl Acad Sci U S A (2014) 0.95
Activated ras regulates the proliferation/apoptosis balance and early survival of developing micrometastases. Cancer Res (2002) 0.95
Loss of pannexin 1 attenuates melanoma progression by reversion to a melanocytic phenotype. J Biol Chem (2012) 0.94
BRMS1 suppresses breast cancer metastasis in multiple experimental models of metastasis by reducing solitary cell survival and inhibiting growth initiation. Clin Exp Metastasis (2008) 0.94
Radiation-induced lung injury after concurrent neoadjuvant chemoradiotherapy for locally advanced breast cancer. Acta Oncol (2014) 0.94
New clinical and experimental approaches for studying tumor dormancy: does tumor dormancy offer a therapeutic target? APMIS (2008) 0.94
Contrast-enhanced microcomputed tomography using intraperitoneal contrast injection for the assessment of tumor-burden in liver metastasis models. Invest Radiol (2008) 0.93
An emerging role for the nuclear localization of maspin in the suppression of tumor progression and metastasis. Biochem Cell Biol (2011) 0.92
Osteopontin induction of hyaluronan synthase 2 expression promotes breast cancer malignancy. J Biol Chem (2006) 0.91
Expression of osteopontin and HGF/met in adult soft tissue tumors. Cancer Biol Ther (2005) 0.91
Human 21T breast epithelial cell lines mimic breast cancer progression in vivo and in vitro and show stage-specific gene expression patterns. Lab Invest (2010) 0.90
Integrin-free tetraspanin CD151 can inhibit tumor cell motility upon clustering and is a clinical indicator of prostate cancer progression. Cancer Res (2013) 0.90
Common phylogenetic origin of protamine-like (PL) proteins and histone H1: Evidence from bivalve PL genes. Mol Biol Evol (2006) 0.90
In vivo single scan detection of both iron-labeled cells and breast cancer metastases in the mouse brain using balanced steady-state free precession imaging at 1.5 T. J Magn Reson Imaging (2011) 0.90
Three-dimensional imaging and quantification of both solitary cells and metastases in whole mouse liver by magnetic resonance imaging. Cancer Res (2009) 0.89
The chick embryo as an expanding experimental model for cancer and cardiovascular research. Dev Dyn (2013) 0.89
In Vivo Magnetic Resonance Imaging for Investigating the Development and Distribution of Experimental Brain Metastases due to Breast Cancer. Transl Oncol (2012) 0.88
Plasma osteopontin levels are predictive of disease stage in patients with transitional cell carcinoma of the bladder. BJU Int (2005) 0.88
High-throughput screening of one-bead-one-compound peptide libraries using intact cells. ACS Comb Sci (2013) 0.88
In vivo videomicroscopy reveals differential effects of the vascular-targeting agent ZD6126 and the anti-angiogenic agent ZD6474 on vascular function in a liver metastasis model. Angiogenesis (2004) 0.88
Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial. Breast Cancer Res (2014) 0.87
Osteopontin expression in normal skin and non-melanoma skin tumors. J Histochem Cytochem (2007) 0.87
Therapeutic targets for antimetastatic therapy. Expert Opin Ther Targets (2004) 0.87
Mapping of functional epitopes of osteopontin by monoclonal antibodies raised against defined internal sequences. J Cell Biochem (2002) 0.87
Mapping of the functional microcirculation in vital organs using contrast-enhanced in vivo video microscopy. Am J Physiol Heart Circ Physiol (2004) 0.86
Sensitivity of cancer cells to truncated diphtheria toxin. PLoS One (2010) 0.86
Putative growth characteristics of micrometastatic breast cancer. Breast Cancer Res (2008) 0.85
Noninvasive quantification of tumor volume in preclinical liver metastasis models using contrast-enhanced x-ray computed tomography. Invest Radiol (2008) 0.85
The thrombin inhibitor Argatroban reduces breast cancer malignancy and metastasis via osteopontin-dependent and osteopontin-independent mechanisms. Breast Cancer Res Treat (2007) 0.85
Effect of anti-fibrinolytic therapy on experimental melanoma metastasis. Clin Exp Metastasis (2008) 0.85
Real-time visualization and quantitation of vascular permeability in vivo: implications for drug delivery. PLoS One (2012) 0.85